Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

TempraMed Signs Definitive Five-Year Saudi Arabia Distribution Agreement for Private ...

25 August 2026 · By · Wire by Fusion42

Published

25 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

Saudi Arabia

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

TempraMed has signed a definitive five-year distribution agreement valued at approximately $3.8 million with Black Olives Company to commercialize a private-label version of VIVI Cap™ through Nahdi Medical Company's pharmacy network in Saudi Arabia, pending regulatory clearance.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

TempraMed's deal opens direct retail access via Saudi Arabia's largest pharmacy chain, boosting your chances to engage pharmacists and consumers physically in the region. Prepare for regulatory deadlines and secure initial orders to capitalise on this retail channel activation.

◆ Coverage

1 source · 25 Aug 2026

◆ Related on Wire

◆ Topics

Medtechdistribution-agreementsaudi-arabiaprivate-labelmedtechpharmacy-chain